Background: Peripheral arterial disease (PAD) is a common risk factor for mortality in hemodialysis (HD) patients. Pentraxin-3 (PTX3), an inflammatory mediator, is widely expressed in peripheral tissues and may have a predictive value for PAD. Objective: To evaluate the role of plasma PTX3 as a predictor for PAD in maintenance HD patients. Patients and Methods: 84 subjects were included; Group 1: 42 End-stage renal disease (ESRD) patients on maintenance HD, and Group 2: 42 Healthy controls. After history taking, examination, and routine laboratory investigations, the following was done; Assessment of lower limb arteries by Color and Pulsed Doppler Ultrasound, ankle-brachial index (ABI), measurement of high-sensitivity C-reactive protein (HS-CRP), and plasma Pentraxin-3 (PTX3) by ELISA. Results: The ABI in HD patients (0.67 ± 0.13) was significantly lower than controls (1.1±0.16), (P<0.001). HS-CRP levels in ng/ml in HD patients (10.5 ± 2.3) were significantly higher than controls (1.48 ± 0.34), (P<0.001). Plasma PTX3 levels in ng/ml in HD patients (6.87 ± 1.36) were significantly higher than controls (1.47 ± 0.25), (P<0.001). Plasma PTX3 had a significant negative correlation with ABI, and Hb% (P<0.001), and a significant positive correlation with cholesterol and triglycerides (P<0.001), whereas HS-CRP did not have correlation with ABI. Plasma PTX3 at a cutoff of 2.35 ng/ml showed a higher predictive value for PAD than HS-CRP at a cutoff of 2.25 ng/ml regarding sensitivity (95.2% vs 88.1%), and specificity (92.0% vs 86.7%) respectively, (P<0.001). Conclusion: Plasma PTX3 maybe used as a predictor for PAD in maintenance HD patients, with a high sensitivity and specificity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.